Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. INDV
INDV logo

INDV Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Indivior Pharmaceuticals Inc (INDV) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Buy
Latest Price
38.480
1 Day change
0.92%
52 Week Range
41.000
Analysis Updated At
2026/06/12
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

INDV is a good buy right now for a beginner with a long-term focus and $50,000-$100,000 to invest. The stock is in a constructive technical uptrend, options sentiment is mildly bullish, and there are no recent negative news or insider/congress selling signals. With no major catalyst risk in the latest news and the price holding above key moving averages, this looks like a reasonable long-term entry now rather than a stock that needs to be waited on.

Technical Analysis

Technically, INDV is trending bullish. The MACD histogram is positive and expanding, indicating strengthening momentum. RSI_6 at 64.1 is elevated but not overbought, suggesting the stock still has room to run. The moving averages are aligned bullishly with SMA_5 > SMA_20 > SMA_200, which is a strong trend confirmation. Current pre-market price is 38.34, just below resistance at R1 38.475 and above the pivot at 35.999, so the stock is trading near a breakout zone. A move through 38.48 could open the path toward R2 at 40.004.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is bullish. The open interest put-call ratio of 0.2 is very low, showing call-heavy positioning. Option volume put-call ratio of 0.0 also indicates no put activity in the reported flow, reinforcing positive sentiment. Implied volatility at 61.52 is above historical volatility of 41.22, showing the market is pricing in meaningful movement. Overall, options data supports a bullish-to-positive outlook.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
3
Buy
9

Positive Catalysts

  • ["Bullish technical structure with SMA_5 > SMA_20 > SMA_200", "Positive and expanding MACD momentum", "Call-heavy options positioning and very low put-call ratio", "No negative news in the past week", "No recent insider selling, hedge fund pressure, or congress trading activity", "Pre-market trading near resistance suggests potential continuation"]

Neutral/Negative Catalysts

  • ["RSI is already in the upper-neutral range, so upside may not be immediate and could be choppy near resistance", "No recent news catalyst in the past week", "No financial snapshot was available, limiting fundamental confirmation", "AI Stock Picker and SwingMax both show no current signal, so this is not an especially strong proprietary-signal setup"]

Financial Performance

No latest quarter financial snapshot was available because of a data error, so I cannot confirm revenue or earnings growth from the provided financials. The most recent quarter season was not provided. Based on the available data, there is no fundamental deterioration signal shown, but the absence of financial detail means the decision is driven mainly by technical and sentiment factors.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price-target trend data was provided, so there is no evidence of a recent Wall Street downgrade or upgrade cycle. From the available information, the Wall Street view appears neutral-to-positive: the bullish price structure and supportive options positioning are favorable, while the lack of fresh analyst revisions means there is no strong external catalyst from brokers either.

Wall Street analysts forecast INDV stock price to rise
5 Analyst Rating
Wall Street analysts forecast INDV stock price to rise
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 38.130
sliders
Low
36
Averages
43.75
High
50
Current: 38.130
sliders
Low
36
Averages
43.75
High
50
Northland
Outperform
upgrade
$40 -> $50
AI Analysis
2026-01-20
Reason
Northland
Price Target
$40 -> $50
AI Analysis
2026-01-20
upgrade
Outperform
Reason
Northland raised the firm's price target on Indivior to $50 from $40 and keeps an Outperform rating on the shares. With legacy overhangs resolved, and capital allocation optionally emerging, the firm views the current valuation as "disconnected from underlying fundamentals" as it raises its FY26 revenue and adjusted EPS estimates.
Morgan Stanley
Overweight
maintain
$28 -> $36
2025-12-03
Reason
Morgan Stanley
Price Target
$28 -> $36
2025-12-03
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on Indivior to $36 from $28 and keeps an Overweight rating on the shares. The firm sees the EU Pharmaceuticals sector set up as neutral into 2026, with fundamentals intact at a low valuation premium compared to history, offset by better EPS growth elsewhere in Europe, the analyst tells investors in a year-ahead outlook note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for INDV
Unlock Now

People Also Watch